Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Multiple Myeloma 5Neoplasms 3Glioma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Rhabdoid Tumor 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × reolysin × Clear all
NCT01274624 2018-12-19

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Oncolytics Biotech

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT02620423 2018-09-13

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Oncolytics Biotech

Phase 1 Completed
11 enrolled
Tumor-Agnostic

Neoplasms

NCT02723838 2017-03-07

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Oncolytics Biotech

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡